IFP Advisors’s Protara Therapeutics TARA Stock Holding History

IFP Advisors’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-2	Closed	-$8	–	5389
2026 Q2	$8	Buy	+2	New	+$10	﹤0.01%	5102

Other funds holding TARA

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return

Indivisible Partners Clearwater, Florida $2.18B AUM 33.61% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

IFP Advisors's TARA Position: Q3 2026 in Review

IFP Advisors sold out of Protara Therapeutics (TARA) in Q3 2026, closing a stake of 2 shares — an estimated $8 sold.

IFP Advisors first reported a position in TARA in Q2 2026 and held it in 1 quarter. The position peaked at $8 in Q2 2026. 24 funds tracked by Wall St. Rank hold TARA as of Q3 2026.

IFP Advisors reported no remaining Protara Therapeutics position as of Q3 2026 after selling out during the quarter.
IFP Advisors sold 2 Protara Therapeutics shares in Q3 2026, an estimated $8.
IFP Advisors first reported a position in Protara Therapeutics in Q2 2026 and held it in 1 quarter.
IFP Advisors's Protara Therapeutics position peaked at $8 in Q2 2026.
24 funds tracked by Wall St. Rank held Protara Therapeutics as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.